Abstract P165 – Table 1. Selected demographics and baseline characteristics by treatment experience and study.
Virologically suppressed switch PWH
Study (N)	Country	Age, median (IQR), ya	Sex, n (%)	Prior duration of ART, median (IQR), ya	Prior ART regimen	CD4+ cell count at switch, cells/mm3, median (IQR)a
Baldin et al, 2019	Italy	51.7	Female	11.5 (6.1 to 18.3)	2 NRTIs + NNRTI: 25.6%, 2 NRTIs + PI: 14.0%, 2 NRTIs + INI: 16.2%, dual therapy: 40.7%	668 (495 to 890)
(N = 556)		(45.3 to 57.4)	165 (29.7)
Calza et al, 2020	Italy	47.1	Male	8.4 (2.6)b	Most common NRTIs: ABC/3TC: 49.1%, TDF/FTC: 45.8%; most common 3rd agent: DTG: 59.3%, bDRV: 18.6%	598 (217)b
(N = 59)		(18.5)b	43 (72.9)
Hidalgo‐Tenorio et al, 2019	Spain	48.5	Male	13 (4 to 18)	Triple therapy: 65.5%, dual therapy: 18.1% (ATV/r + 3TC most common, 37.5%), monotherapy: 16.4% (bDRV most common, 93.1%)	697.7 (337.2)b
(N = 177)		(14.2)b	137 (77.4)
Maggiolo et al, 2021	Multinational (Italy, 94%)	52 (12)	Male	10.2 (13)	NRTI: 93.6% (TDF most common, 59.2%), NNRTI: 49.5% (EFV most common, 18.8%), PI: 32.6% (DRV most common, 14.7%), INI: 22.5% (RAL most common, 11.0%)	669 (446)
(N = 218)			164 (75.2)
Tan et al, 2019	UK	60.5	Male	9.4	TDF: 64%, ABC: 63%, EFV: 48%, DRV/r: 45%	94% with >350 cells/mm3
(N = 52)			44 (84.6)
Yagci‐Caglayik, et al, 2017	Turkey	54	Male	Not reported	PI: 50% (LPV/r: 41%), NNRTI: 13% (EFV: 13%), INSTI: 53% (RAL: 22%, DTG: 22%), TDF/FTC: 66%, 3TC: 25%	272 (131 to 471)
(N = 32)		(41 to 64)c	27 (84.4)
Treatment‐naive PWH
Study (N)	Country	Age, median (IQR), ya	Sex, n (%)		HIV‐1 RNA, median (IQR), copies/mLa	CD4+ cell count, cells/mm3, median (IQR)a
Ciccullo et al, 2021	Italy	34.5	Male		4.78 log10 (4.01 to 5.00)
(N = 20)		(25.2 to 53.5)	15 (75.0)
Deng et al, 2022	China	31	Male		61 100 (33 500 to 229 000)c	222.07 (176.67)b
(N = 27)		(24 to 38)c	27 (100)

^aUnless otherwise indicated;

^bmean (SD);

^cmedian (range).